Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 813 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Attention Deficit-Hyperactivity Clear all

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Non-adaptive Floreo VR control, Floreo Virtual Reality application; Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 8 Years to 16 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Training Executive, Attention and Motor Skills (TEAMS), Parent support and education; Behavioral
Lead sponsor: Queens College, The City University of New York; Other
Eligibility: 48 Months to 71 Months
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Flushing, New York

Conditions: Attention Deficit Disorder
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 10 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: TBI (Traumatic Brain Injury), Brain Injuries, Stress, Attention Deficit, Executive Dysfunction
Interventions: State regulation skill training, Treatment-as-usual; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Maitland, Florida

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more

Conditions: Attention Deficit Disorder With Hyperactivity, Behavioral Insomnia of Childhood
Interventions: Immediate Release Methylphenidate, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 12 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: ADHD
Interventions: Dance Exergaming, Stationary Cycling, Music Listening; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: ADHD, Autism, Bipolar I Disorder, Conduct Disorder, Oppositional Defiant Disorder
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more

Conditions: ADHD
Interventions: atomoxetine (Strattera); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: ADHD
Interventions: Lisdexamfetamine dimesylate (LDX), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Rolling Hills Estates, California • South Miami, Florida • Overland Park, Kansas + 1 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Adderall ® Immediate Release, Adderall XR ®; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: ADHD
Interventions: Aligned sleep extension, Misaligned sleep extension; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: ADHD
Interventions: SPD503-AM, SPD503-PM, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 61
States / cities: Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more

Conditions: ADHD
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Years to 18 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Nicotine Dependence, ADHD
Interventions: Very low nicotine content cigarettes, Conventional nicotine content cigarettes; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Pittsburgh, Pennsylvania

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: NS2359, Placebo; Drug
Lead sponsor: NeuroSearch A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: SPN-810; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine Hydrochloride, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: AEVI-001, Placebo; Drug
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Wayne, Pennsylvania

Conditions: ADHD
Interventions: CLS-A-FUERTE; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 5 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Edivoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 16
States / cities: Spring Valley, California • Gainesville, Florida • Orlando, Florida + 13 more

Conditions: ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
Interventions: Centanafadine, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 46
States / cities: Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 41 more

Conditions: Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD), Attention Deficit Hyperactivity Disorder (ADHD), Schizophrenia Spectrum &Amp; Other Psychotic Disorders, Post Traumatic Stress Disorder, Obsessive Compulsive Disorder (OCD)
Interventions: Solicue Machine Learning Models, Mercuria Machine Learning Models; Diagnostic Test
Lead sponsor: Psyrin Inc.; Industry
Eligibility: 13 Years to 60 Years
Enrollment: 500 participants
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Brookline, Massachusetts • Zanesville, Ohio

Search by objective public record fields.

Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

Non-pharmacological Interventions for Preschoolers With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder and Exposure to Lead

Brain Markers of Improvements in Cognitive Functioning

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD

Effects of Performing Arts on Attention-deficit/Hyperactivity Disorder (ADHD)

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall

Impact of Short and Mistimed Sleep on Adolescents With ADHD: The Adolescent Attention and Circadian Timing Study

Efficacy and Safety of SPD503 in Combination With Psychostimulants

Vascular Effects of Attention Deficit Hyperactivity Disorder (ADHD) Medications in Youth

Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers

Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

Evaluation of Continuous Symptom Treatment of ADHD

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Hybrid Effectiveness-Implementation Trial of a School Clinician Training and Psychosocial ADHD/ODD Intervention Program Adapted for Schools Across Mexico

A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models